Skip to main content
TipRanks
Go Ultimate75% OFF

Purple Biotech (1YI0) Stock Statistics & Valuation Metrics

0 Followers

Total Valuation

Purple Biotech has a market cap or net worth of EUR 9.06M. The enterprise value is -EUR 4.20M.

Market Cap
EUR 9.06M
Enterprise Value
-EUR 4.20M

Share Statistics

Purple Biotech has 1,620,982 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
1,620,982
Owned by Insiders
―
Owned by Institutions
3.16%

Financial Efficiency

Purple Biotech’s return on equity (ROE) is -2.72 and return on invested capital (ROIC) is -272.87%.

Return on Equity (ROE)
-2.72
Return on Assets (ROA)
-1.50
Return on Invested Capital (ROIC)
-272.87%
Return on Capital Employed (ROCE)
-2.80
Revenue Per Employee
0
Profits Per Employee
-2.64M
Employee Count
10
Asset Turnover
0.00
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of Purple Biotech is -0.77. Purple Biotech’s PEG ratio is 0.00.

PE Ratio
-0.77
PS Ratio
0.00
PB Ratio
1.52
Price to FCF
-0.03
Price to Operating Cash Flow
-2.41
PEG Ratio
0.00

Income Statement

In the last 12 months, Purple Biotech had revenue of 0 and earned -26.39M in profits. Earnings per share was -5.50.

Revenue
0
Gross Profit
0
Operating Income
-27.46M
Pretax Income
-26.49M
Net Income
-26.39M
EBITDA
-26.25M
Earnings Per Share (EPS)
-5.50

Cash Flow

In the last 12 months, operating cash flow was -7.76M and capital expenditures 0, giving a free cash flow of -7.76M billion.

Operating Cash Flow
-7.76M
Free Cash Flow
-7.76M
Free Cash Flow per Share
-0.71

Dividends & Yields

Purple Biotech pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-3603.34%
Earnings Yield
-190284.17%

Stock Price Statistics

Beta
―
52-Week Price Change
0.00%
50-Day Moving Average
0.28
200-Day Moving Average
0.28
Relative Strength Index (RSI)
―
Average Volume (3m)
―

Important Dates

Purple Biotech upcoming earnings date is Feb 10, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 17, 2026
Next Earnings Date
Feb 10, 2027
Ex-Dividend Date
―

Financial Position

Purple Biotech as a current ratio of 1.27, with Debt / Equity ratio of 2.51%

Current Ratio
1.27
Quick Ratio
1.27
Debt to Market Cap
0.00
Net Debt to EBITDA
0.32
Interest Coverage Ratio
-704.05

Taxes

In the past 12 months, Purple Biotech has paid 0 in taxes.

Income Tax
0
Effective Tax Rate
0.00

Enterprise Valuation

Purple Biotech EV to EBITDA ratio is 0.17, with an EV/FCF ratio of 0.51.

EV to Sales
0.00
EV to EBITDA
0.17
EV to Free Cash Flow
0.51
EV to Operating Cash Flow
0.51

Balance Sheet

Purple Biotech has EUR 6.11M in cash and marketable securities with EUR 134.00K in debt, giving a net cash position of EUR 5.97M billion.

Cash & Marketable Securities
EUR 6.11M
Total Debt
EUR 134.00K
Net Cash
EUR 5.97M
Net Cash Per Share
EUR 3.68
Tangible Book Value Per Share
EUR 0.45

Margins

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

Gross Margin
0.00%
Operating Margin
0.00%
Pretax Margin
0.00%
Net Profit Margin
0.00%
EBITDA Margin
0.00%
EBIT Margin
0.00%

Analyst Forecast

The average price target for Purple Biotech is EUR 15.32, which is 11.43% higher than the current price. The consensus rating is Moderate Buy

Price Target
EUR 15.32
Price Target Upside
5294.38% Upside
Analyst Consensus
Moderate Buy
Analyst Count
1
Revenue Growth Forecast
―
EPS Growth Forecast
―